

AMENDMENTS TO THE CLAIMS

Please cancel Claims 40-64 and enter the following new claims:

1-64 (Canceled)

65. (New) An isolated protein produced by expression from a first nucleic acid sequence within a nucleic acid molecule, wherein:

(a) said first nucleic acid sequence comprises a means for encoding a *Canine familiaris* B7-2 protein capable of binding a canine CTLA4 or canine CD28 protein or capable of stimulating canine T-cells; and

(b) a second nucleic acid sequence is operatively linked to said first nucleic acid sequence, wherein said second nucleic acid sequence constitutes a means for promoting expression of said first sequence.

66. (New) A therapeutic composition comprising the isolated protein of Claim 65, wherein said composition, when administered to a non-human animal, regulates T-cell mediated immune responses in said non-human animal.

67. (New) The therapeutic composition of Claim 66, wherein said composition comprises a component selected from an excipient, an adjuvant or a carrier.

68. (New) The therapeutic composition of Claim 66, wherein said non-human animal is a canid.

69. (New) An isolated protein encoded by a nucleic acid molecule comprising a nucleic acid sequence at least about 95% identical to a nucleic acid sequence selected from SEQ ID NO:9 or SEQ ID NO:19, wherein said protein is capable of binding a CTLA4 or CD28 protein or is capable of stimulating T-cells.

70. (New) The isolated protein of Claim 69, wherein said protein is encoded by a nucleic acid molecule comprising a nucleic acid sequenced selected from SEQ ID NO:9 or SEQ ID NO:19.

71. (New) The isolated protein of Claim 69, wherein said protein is encoded by a nucleic acid molecule consisting of SEQ ID NO:9 or SEQ ID NO:19.

72. (New) A therapeutic composition comprising the isolated protein of Claim 69, wherein said composition, when administered to a non-human animal, regulates T-cell mediated immune responses in said non-human animal.

73. (New) The therapeutic composition of Claim 72, wherein said composition comprises a component selected from an excipient, an adjuvant or a carrier.

74. (New) The therapeutic composition of Claim 72, wherein said non-human animal is a canid.

75. (New) An isolated protein comprising an amino acid sequence at least about 95% identical to an amino acid sequence selected from SEQ ID NO:7 or SEQ ID NO:17, wherein said isolated protein is capable of binding a CTLA4 or CD28 protein or is capable of stimulating T-cells.

76. (New) The isolated protein of Claim 75, wherein said protein comprises an amino acid sequence selected from SEQ ID NO:7 or SEQ ID NO:17.

77. (New) The isolated protein of Claim 75, wherein said protein consists of an amino acid sequence selected from SEQ ID NO:7 or SEQ ID NO:17.

78. (New) A therapeutic composition comprising the isolated protein of Claim 75, wherein said composition, when administered to a non-human animal, regulates T-cell mediated immune responses in said non-human animal.

79. (New) The therapeutic composition of Claim 78, wherein said composition comprises a component selected from an excipient, an adjuvant or a carrier.

80. (New) (New) The therapeutic composition of Claim 78, wherein said non-human animal is a canid.